Cantor Fitzgerald Reiterates Overweight on Novo Nordisk, Maintains $160 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Novo Nordisk (NYSE:NVO) and maintained a $160 price target.
September 16, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Novo Nordisk, maintaining a $160 price target, indicating confidence in the company's stock performance.
The reiteration of an Overweight rating and maintenance of a $160 price target by a reputable analyst suggests a positive outlook for Novo Nordisk's stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100